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ITIschemia/reperfusion injury in coronary artery bypass grafting: Time
to revisit?T. Bruce Ferguson, Jr, MDSurgical revascularization has demonstrated exceptional du-
rability as a therapeutic intervention for ischemic heart dis-
ease. Objectively, major morbidity and mortality outcomes
have improved steadily over the past 20 years, despite
a well-documented increase in preoperative risk owing to
cardiac and noncardiac comorbidity conditions.1 The overall
risk-adjusted mortality for coronary artery bypass grafting
(CABG) in 1989 exceeded 5%; for 2007 to 2009, the annual
risk-adjusted mortality has hovered around 2.0% nation-
wide according to data from The Society of Thoracic Sur-
geons national database.2 This remarkable improvement
can be attributed to better preoperative patient selection, bet-
ter intraoperative technical and perioperative management
(anesthesia and perfusion technique improvements), and
substantially improved perioperative care, both short term
and long term.
It is of interest, then, that careful evaluation of these data
from The Society of Thoracic Surgeons also documents that
this risk-adjusted mortality for CABG has not continued to
decline over the past 3 years, but rather has remained stable.
Does this potentially suggest that the risk-adjusted mortality
curve has reached its nadir, based on current technology and
techniques, and in fact will start to increase as the preopera-
tive risk continues to steadily increase?
Addressing this question may be more complicated than
first appears. With this low overall risk-adjusted mortality,
substantial improvement in this overall metric cannot be ac-
complished by improvement in the lowest-risk subset of this
overall group. There simply are not enough patients in this
subset with adverse events to affect the overall group metric;
the persistent occurrence of random events in this lowest-
risk subset is what David Eddy3 has characterized as ‘‘the
probabilistic component’’ of medicine.3
It is rather the high-risk group of patients in this overall
subset to which attention needs to be refocused to continue
to drive down the overall operative mortality. Better under-
standing of the impact of pulmonary and/or renal insuffi-
ciency, concomitant hepatic disease, and the structural
components of cardiac care on CABGmorbidity and mortal-
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The Journal of Thoracic andAdditionally, new large-scale randomized trials are being
designed in which conventional concepts of revasculariza-
tion are being re-thought. In the ISCHEMIA and EXCEL tri-
als, both in development, the interventional groups of
cardiologists and surgeons have agreed to a conceptual def-
inition of optimal revascularization that includes 2 compo-
nents, namely, anatomic and ischemic revascularization.
Up to now, the surgical approach has been largely anatomic,
based on grafting of all coronaries with a pre-specified de-
gree of proximal stenosis. As the concept of ischemic revas-
cularization, where only areas with documented ischemia
and significant epicardial arterial stenoses should be revas-
cularized, takes root in percutaneous coronary interventions,
there may be correlates to surgical revascularization that are
documented through these trials to be quite important. In
addition, new technologies are evolving for intraoperative
assessment of both angiographic and functional (ischemic)
components of surgical revascularization.4,5
This brings us back to ischemia/reperfusion. This is the fo-
cus of the methodologic considerations of the RED–CABG
trial (Reduction in Cardiovascular Events by AcaDesine in
Subjects Undergoing CABG), which, if completed, would
be the largest randomized trial in the history of cardiac
surgery. The hypothesis of the trial is that the acadesine,
a first-in-class adenosine-regulating agent, will reduce the
incidence of cardiac and noncardiac ischemia/reperfusion
events in high-risk patients undergoing CABG. Previous tri-
als assessing the use of acadesine in CABG have, in a 1997
meta-analysis,6 been associated with lower odds of perioper-
ative myocardial infarction (MI) and a reduction in the com-
posite incidence of cardiac death, acute MI, or stroke at 4
days postoperatively. The safety profile of acadesine in these
trials documented only a transient hyperuricemia associated
with drug administration. The results of these individual tri-
als were not compelling enough to change clinical practice
despite these promising results. However, these studies
were performed early in the decade of the 1990s, when
many of the cardiac and noncardiac confounding contribu-
tors to CABG mortality were more prevalent than they are
today.
So is it time to revisit ischemia/reperfusion in CABG? The
RED–CABG study outlines a substantial scientific rationale
for the presence of ischemia/reperfusion in CABG, related
both tomyocardial protection and topotential injurious effects
fromcardiopulmonary bypass. TheRED–CABG trial is a ran-
domized, double-blind, placebo-controlled, multinational
clinical study of 7500 high-risk patients designed specifically
to finally answer the question of ischemia/reperfusion in
CABG. Although overall CABG mortality has declined,Cardiovascular Surgery c Volume 141, Number 1 1
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function or, more commonly, other organ-system injury oc-
curring at the time of surgery. Both of these circumstances
would potentially be addressed by an amelioration of ische-
mia/reperfusion injury at the time of surgery.
The primary end point of all-cause mortality, nonfatal
stroke, or need for mechanical support (intra-aortic balloon
pump, ventricular assist device) for severe left ventricular
dysfunction will be assessed in patients undergoing non-
emergency CABG requiring cardiopulmonary bypass and
cardioplegia who are 50 years of age or older, with one or
more of the following risk factors: female gender, prior
CABG, prior MI (except for MI less than 5 days before sur-
gery), prior ischemic stroke, ejection fraction less than or
equal to 30% on imaging within the previous 3 months, or
diabetes mellitus requiring therapy. Patients must have sig-
nificant coronary disease on angiography within the past
12 months, including 50% or greater stenosis of the left
main coronary artery, 70% or greater stenosis of 3 coronary
arteries, or 70% or greater stenosis of 2 coronary arteries,
one of which must be the left anterior descending coronary
artery. Patients withMI greater than 2 years old lose the prior
MI characteristic as a risk factor. The study is confined to pa-
tients undergoing CABG surgery without valve surgery, ex-
cept for mitral valve repair. There are a number of additional
exclusion criteria outlined in the article. The study uses a 1:1
randomized treatment assignment within 24 hours before the
scheduled operation, stratified by gender. Patients are ran-
domized to receive placebo intravenous infusion beginning
30 minutes before anesthesia and continuing for 7 hours
postoperatively or the acadesine intravenous infusion over
the same time frame. Follow-up at 28 days for the primary
end point and by telephone at 6 months for survival is pro-
scribed. Although robust, this protocol is very adaptable
and applicable for most high-risk patients undergoing
CABG with cardiopulmonary bypass. As scheduled, 2 futil-
ity analyses will be performed, at 2250 and then and again at
3000 patients enrolled.
Importantly, the mechanism of action of acadesine at the
cellular level is still unknown; however, it remains the lead-
ing candidate adenosine-regulating agent, has a safety pro-
file already validated in the setting of CABG, and has
potential applicability to other areas of ischemia/reperfusion2 The Journal of Thoracic and Cardiovascular Surgerif RED–CABG yields a positive result. This includes, for ex-
ample, potential applicability in the complex setting of acute
coronary syndrome.
Finally, RED–CABG is a critically important trial for the
cardiac surgical community. As was the case with the PRE-
VENT IV trial,7 RED–CABG is likely to yield significant
new and important information regarding contemporary sur-
gical revascularization. The potential to positively affect
CABG outcomes by amelioration of ischemia/reperfusion
is more likely to be demonstrable today as opposed to 20
years ago, for the reasons outlined above; this circumstance
also makes it more likely that pharmacologic intervention,
rather than technical issues or processes of care, will generate
a positive impact. Importantly, the setting of cardiac surgery,
represented here by CABG, has not been highly evaluated or
used for pharmacologic intervention evaluations, and thus
RED–CABG represents an important opportunity for this
reason.
Amelioration of ischemia/reperfusion may be the neces-
sary next step in the cardiac surgeon’s continuing efforts to
drive down perioperative mortality andmorbidity in contem-
porary CABG. The entire cardiac surgery community ea-
gerly awaits the results of the RED–CABG trial intervention.References
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